Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

Asthma
Glenmark-Celon Can Launch Gx Seretide Accuhaler In Certain Markets • Source: Shutterstock

Glenmark Pharmaceuticals Ltd.’s Europe operations reported a dull third quarter but the firm expects a pick up in the business going forward, aided in part by a settlement pertaining to Salmex (fluticasone/salmeterol), its partnered generic version of GlaxoSmithKline PLC’s Seretide Accuhaler dry powder inhaler.

Glenmark said that the settlement agreement concluded with GSK will allow it and Polish partner Celon Pharma SA to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip